$CIPLA Record Revenue, Falling Profit | The Cipla Paradox

$CIPLA Healthcare stocks were among the sectors seeing buying interest in today's session — and Cipla was among the standout names, featuring as one of today's top Nifty gainers alongside Eternal and Titan. The buying is happening despite — or perhaps because of — a Q1 FY27 result that presented two very different stories in the same set of numbers. Cipla reported its highest-ever Q1 revenue of Rs 7,119 crore, yet EBITDA margins fell to 16.7 per cent — well below the company's own full-year guidance of 18.5 to 20 per cent. Net profit of Rs 789 crore represented a sharp decline of 39.19 per cent year on year, even as it recovered 42.26 per cent sequentially from the previous quarter. Management attributed the margin squeeze to war-related cost inflation, higher inventory charges and launch-related spending — framing these as temporary headwinds rather than structural issues. The longer-term picture is more reassuring. The 52-week range runs from Rs 1,165.70 to Rs 1,673, with the stock currently at Rs 1,461 — up 9.6 per cent over the past six months but still 5.67 per cent below year-ago levels. Analyst consensus target stands at Rs 1,512.86, with a high target of Rs 1,768 — implying meaningful upside if the margin recovery management has guided for materialises in Q2 and Q3. Market cap stands at Rs 1.19 lakh crore with mutual fund shareholding at 20.56 per cent as of today. The market's logic today appears straightforward: a record revenue quarter with temporary margin pressure in a structurally growing pharma company is a buying opportunity, not a reason to exit. Whether that thesis holds through Q2 results will be the real test.